4D Molecular Therapeutics, Inc.
FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial foā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.18
Price+1.09%
$0.11
1Y
Price
Market Cap
$532.172m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-61794.4%
EBITDA Margin-63195.6%
Net Profit Margin-51563.3%
Free Cash Flow Margin-61794.4%
EBITDA Margin-63195.6%
Net Profit Margin-51563.3%
Free Cash Flow MarginRevenue
$88.242m
+224.3%
1y CAGR+228.9%
3y CAGR+151.0%
5y CAGREarnings
-$160.897m
-30.0%
1y CAGR-27.8%
3y CAGR-33.5%
5y CAGREPS
-$2.66
-25.8%
1y CAGR-8.0%
3y CAGR-12.7%
5y CAGRBook Value
$451.836m
$512.905m
Assets$61.069m
Liabilities$20.535m
DebtDebt to Assets
4.0%
-0.1x
Debt to EBITDAFree Cash Flow
-$130.055m
-33.7%
1y CAGR-29.9%
3y CAGR-28.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company